New research indicates that people who discontinue new slimming jabs like Wegovy and Mounjaro tend to recover shed pounds much more quickly than those who stop conventional lifestyle plans.
Findings released in a major medical journal demonstrates that while obese people often shed a large proportion of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month upon discontinuation.
"People purchasing such medications must be cognizant of the risk of rapid weight regain when the therapy ends," stated lead investigator Dr. Susan Jebb.
That rate of recovery means a return to original mass within about 18 months.
Comparing Treatments
The research, which examined 37 of trials involving thousands of participants, compared the outcomes of these new drugs with other pills.
Researchers point out that people who lose weight through diet and exercise usually see a slower weight regain—perhaps 100 grams monthly—after stopping.
Understanding the Quick Rebound
Doctors believe the way of the jabs accounts for the amplified rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations several times higher than normal may cause the system to produce less of its own natural GLP-1, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating far more likely."
A Lifelong Disease?
Medical guidelines suggest the jabs for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, due to the significant potential of weight regain, the therapy should be considered ongoing.
This view is reinforced by drug manufacturers, who note that the results "emphasize the chronic character of excess weight," akin to managing conditions like hypertension.
User Testimonies
Individuals who have come off the jabs explain a intense return of appetite.
"It was like something that goes on and you become ravenous," recalled one woman.
The struggle is exacerbated if individuals have not established sustainable dietary or behavioural changes during therapy.
Significant Interest
Recent estimates show that millions of people in the UK have tried these injections in the last 12 months, with desire being substantial.
- Use is more common among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent cure and lasting health benefits likely depends on ongoing behavioural support.
